DNA methylation inhibition in myeloma: experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose …
J Khouri, BM Faiman, D Grabowski, RZ Mahfouz… - Seminars in …, 2021 - Elsevier
The DNA methyltransferase inhibitor azacytidine (aza) may reactivate pathways associated
with plasma cell differentiation, cell cycle control, apoptosis, and immune recognition and
thereby restore sensitivity to lenalidomide (len) and dexamethasone (dex) in relapsed
and/or refractory multiple myeloma (RRMM). We aimed to develop an aza regimen that
reaches epigenetically active levels 8 times in 28 days with less bone marrow toxicity than
the myeloid malignancy standard of 7 consecutive doses to enable safe combination with …
with plasma cell differentiation, cell cycle control, apoptosis, and immune recognition and
thereby restore sensitivity to lenalidomide (len) and dexamethasone (dex) in relapsed
and/or refractory multiple myeloma (RRMM). We aimed to develop an aza regimen that
reaches epigenetically active levels 8 times in 28 days with less bone marrow toxicity than
the myeloid malignancy standard of 7 consecutive doses to enable safe combination with …
